Investor Relations

News Releases

News Releases

September 26, 2018
RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference
- RXi to present a poster today, Wednesday, September 26, 2018 - Advancements in the Company's immuno-oncology programs will be presented demonstrating the potential of sd-rxRNA in NK cells for the use in adoptive cell therapy (ACT) - Data further expands the broad applicability of sd-rxRNA for the
Additional Formats
August 15, 2018
RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors

MARLBOROUGH, Mass. , Aug. 15, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it has entered

Additional Formats